Acute myeloid leukemia, Blood cancer, Cancer
KURAKura OncologyCatalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for Ziftomenib + gilteritinib in Acute myeloid leukemia, Blood cancer, Cancer. The expected timing is based on the latest available company guidance and may change.
KOMET-008 trial. 2/26/24- First patient dosed. 2/28/25- Dosing of all participants in all cohort is ongoing. 11/04/25:- Plan prelim Ph1 gilteritinib combo data in 2026. 01/11/26:- Plan KOMET-008 gilteritinib cohort preliminary data presentation in H2 2026. 03/05/26:- H2 2026 preliminary KOMET-008 ziftomenib plus gilteritinib R/R NPM1-m/FLT3-m AML data reiterated. 05/12/26:- KOMET-008 enrollment ongoing; preliminary ziftomenib plus gilteritinib R/R NPM1-m/FLT3-m AML data still expected H2 2026. 08/12/26:- KOMET-008 enrollment continues. Initial data is expected in H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.